NCT03074630View on ClinicalTrials.gov

Dapagliflozin and Cholesterol Metabolism in Type 2 Diabetes (DM2)

PHASE4CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions
Diabetes Mellitus, Type 2Hypercholesterolemia
Interventions
DRUG

Dapagliflozin

5 weeks 10mg dapagliflozin once daily

DRUG

Rosuvastatin

9 weeks 10mg dapagliflozin once daily

Trial Locations (1)

1105AZ

Academic Medical Center, Amsterdam

All Listed Sponsors
collaborator

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

lead

Amsterdam UMC, location VUmc

OTHER

NCT03074630 - Dapagliflozin and Cholesterol Metabolism in Type 2 Diabetes (DM2) | Biotech Hunter | Biotech Hunter